SARS-CoV-2 : 코로나-19 바이러스 환자의 임상 관리, 표적화 연구
- 저자Joaquim Bosch-Barrera, Begona Martin-Castillo,Maria Buxo, Joan Brunet , Jose Antonio Encina
- 출판사아진
- 출판일2020-07-12
- 등록일2020-12-21
- SNS공유
- 파일포맷PDF
- 파일크기10MB
- 공급사YES24
-
지원기기
PC
PHONE
TABLET
프로그램 수동설치
전자책 프로그램 수동설치 안내
아이폰, 아이패드, 안드로이드폰, 태블릿,
보유 1, 대출 0,
예약 0, 누적대출 7, 누적예약 0
책소개
COVID-19, the illness caused by infection with the novel coronavirusSARS-CoV-2, is a rapidly spreading global pandemic in urgent need of eective
treatments. Here we present a comprehensive examination of the host- and
virus-targeted functions of the flavonolignan silibinin, a potential drug candidate
against COVID-19/SARS-CoV-2. As a direct inhibitor of STAT3?a master
checkpoint regulator of inflammatory cytokine signaling and immune response?
silibinin might be expected to phenotypically integrate the mechanisms of action of
IL-6-targeted monoclonal antibodies and pan-JAK1/2 inhibitors to limit the
cytokine storm and T-cell lymphopenia in the clinical setting of severe COVID-19.
As a computationally predicted, remdesivir-like inhibitor of RNA-dependent RNA
polymerase (RdRp)?the central component of the replication/transcription
machinery of SARS-CoV-2?silibinin is expected to reduce viral load and impede
delayed interferon responses.
The dual ability of silibinin to target both the host cytokine storm and the virus
replication machinery provides a strong rationale for the clinical testing of silibinin
against the COVID-19 global public health emergency. A randomized, open-label,
phase II multicentric clinical trial (SIL-COVID19) will evaluate the therapeutic
ecacy of silibinin in the prevention of acute respiratory distress syndrome in
moderate-to-severe COVID-19-positive onco-hematological patients at the Catalan
Institute of Oncology in Catalonia, Spain.
목차
제 1편 코로나바이러스 정의1. 코로나바이러스감염증-19(Covid-19) 정보 7
2. 코로나바이러스 분류 및 특성 9
3. 코로나바이러스 전자현미경 형태 11
4. 코로나바이러스 구조 (Covid-19 Organization) 13
5. 코로나19: 환경에 지속적인 영향을 미칠까? 19
6. 치료법(Therapeutical Method) 22
제 2편 연구논문
Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm
and Virus Replication Machinery for Clinical Management of COVID-19
Patients
1. Abstract 23
2. Introduction 23
3. Silibinin: From an Old Remedy to a Direct STAT3 Inhibitor 25
4. Silibinin and STAT3:Targeting the(Reactive)Cytokine Storm 29
5. Silibinin and the RNA-Dependent RNA Polymerase Complex:
Targeting Virus Replication 32
6. Silibinin and COVID-19: An Ongoing Clinical Trial 34
7. Silibinin and SARS-CoV-2: An Early-Intervention in Older
Individuals at Risk ofSevere COVID-19? 35
8. Conclusions 37
9. References 38
